Lege Artis Medicinae

[Substitution of drugs with narrow therapeutic window in transplant immunology]

LANGER Róbert, TÖRÖK Szilárd

DECEMBER 18, 2012

Lege Artis Medicinae - 2012;22(12)

[Because of the economic crisis affecting the health care system, the Hungarian government have envisaged a number of measures. In Hungary, the system of reference support or fixing is an excellent cost-saving tool in the financing of drugs that have a similar mechanism of effect or contain the same molecule. However, in case of certain patient groups and of “critical drugs”, it is to be feared that an inadequate agent might actually bring loss rather than benefit. In this paper, we would like to draw attention to the fact that switching the original microemulsion cyclosporin to generic, no-microemulsion preparations might pose a direct risk for the safety of the transplanted organ and the transplanted patient.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Invictus – The Road to Reconciliation ]

FERENCZI Andrea

Lege Artis Medicinae

[Is a Good Death Possible? ]

HEGEDÛS Katalin

Lege Artis Medicinae

[Lajos Gulácsy, the Masked One ]

CZEIZEL Endre

Lege Artis Medicinae

[The Man who Compiled the First Russian Pharmacopoeia – Keresztély Peken (1730-1779) ]

V. MOLNÁR László

Lege Artis Medicinae

[The Art of Cézanne – An Exhibition in Budapest ]

NAGY Zsuzsa

All articles in the issue

Related contents

Hypertension and nephrology

[The safety and efficacy of LCP-tacrolimus in maintenance immunosuppressive therapy after kidney transplantation]

CSEPREKÁL Orsolya, KEGLEVICH András, REMPORT Ádám

[This paper provides a comprehensive review of a new, innovative formulation of one of the cornerstones of immunosuppressive maintenance therapy, tacrolimus (LifeCycle Pharma Tac, LCP-Tac, LCPT). This brief overview provides a deeper insight into the scientific literature of LCP-Tac. In summary, once daily LCP-Tac, a medication available in routine clinical practice, can provide effective and safe blood levels in renal transplant patients. Furthermore LCP-Tac may require lower doses of tacrolimus due to increased bioavailability thanks to the innovative MeltDose® technology.]

Lege Artis Medicinae

[Efficiency and safety of the vaccination against H1N1 influenza virus in inflammatory bowel disease]

FARKAS Klaudia, JANKOVICS István, MELLES Márta, NAGY Ferenc, SZEPES Zoltán, WITTMANN Tibor, MOLNÁR Tamás

[INTRODUCTION - Inactivated influenza and H1N1 vaccination is recommended yearly for patients with inflammatory bowel disease receiving immunosuppressive therapy; however, immunomodulator and biological therapy might impair the immune response to the vaccination. In our study, we assessed whether immunity can develop in response to H1N1 influenza vaccination in patients receiving immunomodulator and/or biological therapy. We also assessed the occurrence of side effects after the immunisation in these patients. PATIENTS AND METHODS - In our prospective study, blood samples were obtained from 24 patients (12 Crohn’sdisease, 12 ulcerative colitis) one month after immunisation against influenza A/California/ 07/2009 (H1N1) virus. At the time of vaccination, all patients have been receiving immunomodulator and/or biological therapy for at least three month. Antiviral antibodies were detected by using microneutralisation assay. The safety of the vaccination was assessed by questionnaires. RESULTS - Every patient developed complete immunity against influenza A (H1N1) virus, independently from the type of immunosuppressive therapy. Regarding side effects, local symptoms occurred in six patients and systemic symptoms in another six patients. Mild diarrhea occurred in five patients. Moderate exacerbation of the disease was observed in 2 patients with Crohn’s disease and in one patient with ulcerative colitis. CONCLUSIONS - According to our results, immunocompromised patients with IBD can be safely advised to receive the vaccination. In our study, all patients developed adequate immunity according to microneutralisation titers.]

Lege Artis Medicinae

[Management of inhibitory haemophilia A and aquired haemophilia]

PFLIEGLER György, RÁK Kálmán, KRÁLL Géza, SAS Géza, HAYNAL Imre

[The authors survey the occurrence and the laboratory and clinical differences of factor VIU antibodies in haemophiliacs (allo) and in non-haemophiliacs (auto) as well as their titer and measurement. The recent therapeutic modalities used in prevention, management of acute bleeds and suppression of antibody development or in duction of immune tolerance are detailed. ]

Hypertension and nephrology

[Prominents in Hungarian nephrology Professor Gyula Petrányi (1912-2000). Part II]

SZALAY László

[A nation can only survive and keep its identity through its traditions. This is why the initiative to launch this series coming from professor János Radó is worthy of attention. Gyula Petrányi is an outstanding personality in 20th century internal medicine, to be more precise in nephrology and immunology, his activity being wide-ranging. The first part of the current summary of his work deals with a tribute to his personality, and his role in immunomodularity treatment in glomerulonephritis. The second part shall cover his role in spreading renal biopsy, screening and caring kidney patients, dialysis, in developing kidney patients’ care, furthermore in clinicopharmacology and renal transplantation.]

Hypertension and nephrology

[Covid-19 and the kidney]

PATÓ Éva, DEÁK György

[Covid-19 pandemy has emerged from Wuhan, China in December 2019. The infection affects not only the lung but other organs such as the kidney, as well. The relation between Covid-19 infection and the kidney is bidirectional. On one hand, Covid-19 infection may cause kidney damage in 50-75% of the cases resulting in proteinuria, haematuria and acute kidney injury (AKI). The etiology of AKI is multifactorial. Main pathogenic mechanisms are direct proximal tubular cell damage, sepsis-related haemodinamic derangement, citokine storm and hypercoagulability. The virus enters proximal tubular cells and podocytes via the ACE2 receptor followed by multiplication in the lysomes and consequential cell lesion. Histopathology shows acute tubular necrosis and acute tubulointerstitial nephritis. AKI is a strong predictor of mortality in critically ill patients. On the other hand, the risk of Covid-19 infection and mortality is substantially increased in patients with chronic kidney disease – especially in those with a kidney transplant or on dialysis – due to their immunocompromised status. Among haemodialysis patients, infection may spread very easily due to the possibility of getting contacted in the ambulance car or at the dialysis unit. The mortality rate of patients on renal replacement therapy with Covid-19 infection is 20-35%. In order to avoid mass infection it is obligatory to employ preventive measures and implement restricions along with (cohors) isolation of infected patients. In Hungary, every dialysis or kidney transplant patient with Covid-19 infection should be admitted to dedicated Covid-19 wards.]